Reuters
05 Jun 2026, 23:31 UTC · 21w ago
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Impact · against what's priced in
Roche's mid-stage trial results establish the company as a viable competitor in the obesity market with efficacy data (22.7% average weight loss) that puts it in the high-performance tier. This creates a new growth catalyst for the valuation as the drug demonstrates potential to be a best-in-class contender.
- ROG+0.70
No priced-in read yet
- In context
The 22.7% average weight loss and the fact that over 25% of high-dose patients hit 30% weight loss provide concrete evidence of the drug's competitiveness in the GLP-1 space.
Read from the article alone
Search tags
